Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interleukin-15-activated CD56+ cells
- Development stage
- Unknown
- Lead developer
- Shahid Beheshti University of Medical Sciences
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Interleukin-15-activated CD56+ cells is an investigational adoptive cell-based immunotherapy consisting of donor-derived natural killer (NK) and natural killer T (NKT) cells. The therapy involves the isolation of CD56+ cells from non-mobilized donors, followed by ex vivo activation through overnight incubation with the cytokine interleukin-15 (IL-15). This activation process is designed to enhance the cells' cytotoxic potential, increase the expression of activating receptors, and improve their anti-leukemic immune response. Primarily developed for the treatment of high-risk acute myeloid leukemia (AML) in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), the therapy aims to provide a potent graft-versus-leukemia effect to reduce the risk of relapse while maintaining a favorable safety profile.
- Other names
- IL-15-activated CD56+ cellsIL-15-activated natural killer cellsIL15-activated natural killer cellsIL 15-activated natural killer cellsinterleukin-15-activated NK cellsinterleukin15-activated NK cellsinterleukin 15-activated NK cells
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on interleukin-15-activated CD56+ cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interleukin-15-activated CD56+ cells.